Survodutide for Health & Longevity

Created on 10/30/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Survodutide, an experimental, unapproved weekly injection for obesity and fatty liver disease, copies two hormones: one curbs appetite, one pushes the liver to burn stored fat. Trials against placebo show substantial weight loss, better blood sugar control and less liver fat and inflammation. Nausea, vomiting and diarrhea are common during dose increases; resting heart rate rises slightly. Evidence is almost entirely developer-funded; no study has looked at lifespan or aging. (Full Review)

Protocol

Obesity regimen
3.6 mg or 6.0 mg once weekly
Subcutaneous injection after escalation, with diet and activity counseling for about a 500 kcal daily deficit; trial protocol, no approved dose
Escalation
Over 20-24 weeks
Starts low and steps up every few weeks, pausing or stepping back one level when gastrointestinal symptoms are significant
Liver-focused regimen
6.0 mg weekly
Phase 3 dose; in phase 2, 4.8 mg gave the highest liver response
Time to effect
Weight loss
Continues through 76 weeks
Appetite falls within the first weeks; weight loss continued through 46 weeks in phase 2 and 76 weeks in phase 3
Blood glucose
16-48 weeks
HbA1c lowered at 16 weeks in phase 2 and at 48 weeks in phase 3
Liver fat
16-48 weeks
Liver fat and inflammation reduced at 48 weeks in phase 2 biopsy and phase 3 imaging

Benefits

Contraindications
  • Personal or family history of medullary thyroid carcinoma or MEN 2
  • Pregnancy or planned pregnancy
  • Severe gastroparesis
  • Prior serious hypersensitivity to GLP-1-acting drugs
  • History of pancreatitis
  • Type 1 diabetes
  • Uncontrolled tachyarrhythmia
Key Interactions
  • Oral drugs, including acetaminophen and narrow-margin drugs (warfarin, levothyroxine)
  • Insulin and insulin secretagogues, such as sulfonylureas (glimepiride, gliclazide)
  • Other GLP-1-acting drugs (semaglutide, tirzepatide): co-use not recommended
  • General anesthesia or deep sedation
Theoretical (inferred from mechanism)
  • Oral hormonal contraceptives (ethinyl estradiol with levonorgestrel)
  • Drugs cleared by CYP enzymes (bupropion, midazolam)
  • Nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen)
  • Antihypertensives: angiotensin receptor blockers (losartan), ACE inhibitors (lisinopril), diuretics (hydrochlorothiazide)
  • Glucose-lowering supplements (berberine, chromium picolinate)
  • Blood-pressure-lowering supplements (beetroot nitrate, garlic extract)
  • Bulk fibers and laxative supplements (glucomannan, psyllium)
  • Alcohol
  • Very-low-calorie diets, prolonged fasting or bariatric surgery

Risk & Side Effects

  • High: Gastrointestinal adverse events and treatment discontinuation; resting heart rate increase
  • Medium:
  • Low: Lean-mass and bone loss; low blood pressure; gallbladder disease; pancreatitis and pancreatic enzyme elevation; acute kidney injury from fluid loss; diabetic retinopathy complications; mood changes and suicidal ideation; hypoglycemia with insulin or sulfonylureas; hypersensitivity reactions; pulmonary aspiration during anesthesia; weight regain after stopping
  • Speculative: Thyroid C-cell tumors; amino acid lowering and muscle protein

Monitoring

Marker Target Why
Body weight and waist circumference No established target; percent change from own baseline Primary effect
HbA1c 4.0-5.6% Glucose control
Fasting glucose 70-99 mg/dL Hypoglycemia on insulin or sulfonylureas
Triglycerides Below 150 mg/dL Lipid effect
ALT About 7-55 U/L, lab-specific Liver inflammation
Liver fat by MRI-PDFF Below 5% Liver-fat response
Resting heart rate 60-100 beats per minute Heart-rate increase
Blood pressure No established target; change from own baseline and symptoms on standing Hypotension; expected to fall
Creatinine and eGFR Creatinine about 0.6-1.3 mg/dL Kidney injury from fluid loss
Lipase and amylase Below the lab's upper limit of normal Pancreatitis
Lean mass by DEXA No established target; appendicular lean mass change from own baseline Lean-mass loss

Cadence: Baseline before starting; weight, heart rate and blood pressure weekly at home during escalation; laboratory tests at 12 weeks, then every 3-6 months during the first year and every 6-12 months thereafter; liver imaging and DEXA at 12 months

Qualitative Assessment

  • Appetite, fullness after meals and fewer intrusive thoughts about food
  • Nausea, vomiting, bowel habits and abdominal pain
  • Energy levels, exercise tolerance and strength
  • Palpitations or dizziness on standing
  • Mood and sleep quality